BMS initiates trial for Imzokitug in NSCLC with Pumitamig and chemotherapy
Bristol-Myers Squibb is conducting a study to evaluate Imzokitug combined with Pumitamig and PDCT in NSCLC.
Asset / Drug
Drug and asset intelligence for Imzokitug with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.